表紙
市場調查報告書

持續血糖監測系統(CGM)市場 - 成長,趨勢,預測(2020年∼2025年)

Continuous Glucose Monitoring (CGM) Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 930801
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
持續血糖監測系統(CGM)市場 - 成長,趨勢,預測(2020年∼2025年) Continuous Glucose Monitoring (CGM) Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年04月02日內容資訊: 英文
簡介

持續血糖監測系統(CGM)的市場規模,在本報告的預測期間內以超越12%的年複合成長率擴大。

在北美,美國佔2019年的市場價值的近94%。2020年,美國的持續血糖監測系統市場,預計達到11億美元。美國的持續血糖監測系統市場,預計在預測期間內記錄約10.8%的年複合成長率。CGM設備與胰島素幫浦必須一同使用。為了糖尿病管理使用胰島素幫浦的糖尿病患者有增加的趨勢,CGM設備銷售台數也預計追隨。

本報告提供全球持續血糖監測系統(CGM)市場調查,市場概要,各零組件、地區的市場規模的變化與預測,市場成長要素及阻礙因素,市場機會,競爭情形,主要企業的簡介等,全面性資訊。

目錄

第1章 簡介

  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 促進因素
  • 阻礙因素
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 競爭加劇

第5章 市場區隔

  • 各零件
    • 持續性血糖監測系統
  • 各地區
    • 北美
    • 歐洲
    • 南美
    • 亞太地區
    • 中東、非洲地區

第6章 市場指標

  • 第一型糖尿病人口
  • 第二型糖尿病人口

第7章 競爭情形

  • 企業簡介
    • Abbott Diabetes Care
    • Dexcom
    • Medtronic

第8章 市場機會及未來趨勢

目錄

Market Overview

The Continuous Glucose Monitoring (CGM) Market is anticipated to register a CAGR of over 12% during the forecast period. As per WHO data, approximately half of all mortality can be associated with high blood glucose levels, which occur before the age of 70 years. WHO also expects diabetes to be the seventh-leading cause of mortality by 2030. For patients reliant on insulin pumps or daily insulin injections, the CGM establishes itself to be an instrumental tool, which helps in the enhancement of glycemic balance without increasing the danger of fatal hypoglycemia. As studied in several clinical trials, diabetic patients with Type 1 diabetes mellitus (T1DM) using continuous glucose monitoring have been shown to have better glycemic control, in comparison to when glucometer is used for routine self-monitoring blood glucose. The trend follows in children, as well as those who use a CGM on a regular basis. The results in these children show better-glycosylated haemoglobin (HbA1c) levels without an amplified frequency of hypoglycemia. The current CGM models approved administer glucose oxidase-based electrochemical subcutaneous sensors for the detection of glucose levels in the interstitial fluid. CGM devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. Most of the real-time CGMs can offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, to facilitate timely management of blood glucose.

Scope of the Report

By the component, the market has been segmented into sensors and receivers. The study offers a detailed analysis on the use of CGM and also provides market share, size, forecast, and industry overview.

Key Market Trends

The market for CGM is on the rise

CGMs are used to provide a further descriptive representation of blood glucose patterns and tendencies than what can be achieved by conventional routine checking of glucose levels at set intervals. The current CGM devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. Most of the real-time CGMs have the capability to offer an alert to patients, parents, or caregivers during actual or pending glycemic visits, to facilitate timely management of blood glucose. This factor, along with the fact that CGM devices are becoming cheaper with the advent of new technologies, like cell phone integration, is likely to drive the steady growth of the CGM market during the forecast period.

North America will Maintain Dominance in the Market

In North America, the United States accounted for close to 94% of the market value in 2019. By 2020, the continuous glucose monitoring market in the United States is expected to be valued at USD 1.1 billion. The Continuous Glucose Monitoring Market in the US is anticipated to register a CAGR of about 10.8% during the forecast period. It is imperative that the CGM devices be used alongside insulin pumps. As the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of CGM devices sold will also follow. As the trend shows a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of CGM devices sold will also follow a similar trend in the coming years.

Competitive Landscape

A major share of the market is held by CGM manufacturers that are concomitant with strategy-based M&A operations and are constantly entering new markets to generate new revenue streams and to boost existing ones. These measures taken by the market players will ensure a competitive market place, therefore, forcing the companies to experiment with more new technologies, to ensure uniqueness in their products. Also, one of the implications of the competition in the market is that it will ensure a constant decrease in the average selling price of the CGM units produced. The market is consolidated with few players accounting for a major share. Also, companies are collaborating to increase their technological know-how and to fasten the product development cycle. For instance, in June 2019, Dexcom and Companion Medical announced a collaboration to integrate Dexcom CGM Data and InPen Insulin Data. Earlier, in December 2017, Abbott's new FreeStyle Libre Flash Glucose Monitoring System was approved, which is the first continuous blood sugar monitor for people with diabetes that does not need backup finger prick tests. Abbott has also priced the new device substantially lower than its competitors, which will help the company to strengthen its position in the CGM market during the forecast period.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Drivers
  • 4.3 Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. Market Segmentation

  • 5.1 By Component (Value and Volume, 2012 - 2025)
    • 5.1.1 Continuous Blood Glucose Monitoring
      • 5.1.1.1 Sensors
      • 5.1.1.2 Receivers
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States (Value and Volume, 2012 - 2025)
      • 5.2.1.2 Canada (Value and Volume, 2012 - 2025)
      • 5.2.1.3 Rest of North America (Value and Volume, 2012 - 2025)
    • 5.2.2 Europe
      • 5.2.2.1 France (Value and Volume, 2012 - 2025)
      • 5.2.2.2 Germany (Value and Volume, 2012 - 2025)
      • 5.2.2.3 Italy (Value and Volume, 2012 - 2025)
      • 5.2.2.4 Spain (Value and Volume, 2012 - 2025)
      • 5.2.2.5 United Kingdom (Value and Volume, 2012 - 2025)
      • 5.2.2.6 Russia (Value and Volume, 2012 - 2025)
      • 5.2.2.7 Rest of Europe (Value and Volume, 2012 - 2025)
    • 5.2.3 Latin America
      • 5.2.3.1 Mexico (Value and Volume, 2012 - 2025)
      • 5.2.3.2 Brazil (Value and Volume, 2012 - 2025)
      • 5.2.3.3 Rest of Latin America (Value and Volume, 2012 - 2025)
    • 5.2.4 Asia-Pacific
      • 5.2.4.1 Japan (Value and Volume, 2012 - 2025)
      • 5.2.4.2 South Korea (Value and Volume, 2012 - 2025)
      • 5.2.4.3 China (Value and Volume, 2012 - 2025)
      • 5.2.4.4 India (Value and Volume, 2012 - 2025)
      • 5.2.4.5 Australia (Value and Volume, 2012 - 2025)
      • 5.2.4.6 Vietnam (Value and Volume, 2012 - 2025)
      • 5.2.4.7 Malaysia (Value and Volume, 2012 - 2025)
      • 5.2.4.8 Indonesia (Value and Volume, 2012 - 2025)
      • 5.2.4.9 Philippines (Value and Volume, 2012 - 2025)
      • 5.2.4.10 Thailand (Value and Volume, 2012 - 2025)
      • 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012 - 2025)
    • 5.2.5 Middle-East and Africa
      • 5.2.5.1 Saudi Arabia (Value and Volume, 2012 - 2025)
      • 5.2.5.2 Iran (Value and Volume, 2012 - 2025)
      • 5.2.5.3 Egypt (Value and Volume, 2012 - 2025)
      • 5.2.5.4 Oman (Value and Volume, 2012 - 2025)
      • 5.2.5.5 South Africa (Value and Volume, 2012 - 2025)
      • 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2012 - 2025)

6. MARKET INDICATORS

  • 6.1 Type 1 Diabetes Population (2012-2025)
  • 6.2 Type 2 Diabetes Population (2012-2025)

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Abbott Diabetes Care
    • 7.1.2 Dexcom
    • 7.1.3 Medtronic

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

** Subject to Availability.